Page 13 - Dror Bashan News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Protalix BioTherapeutics Seeks Multiple Collaborative Partnerships To Complement Core Platform JERUSALEM (dpa-AFX) - Protalix BioTherapeutics, Inc. (PLX), a biopharmaceutical company, said Wednesday that its President and Chief Executive Officer Dror Bashan has sent an annual letter to the company's shareholders and the investment community. In the 2020 letter to shareholders, Bashan said that together with Chiesi Global Rare Diseases, the company's development and commercialization partner, it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration or FDA...

Protalix BioTherapeutics Issues 2020 Letter to Shareholders USA - English Share this article Share this article CARMIEL, Israel, Dec. 30, 2020 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx ® plant cell-based protein expression system, today announced the following letter from its President and Chief Executive Officer, Dror Bashan, to its shareholders and the investment community. Dear Protalix sha...

Protalix & Chiesi: Phase III BRIDGE Trial Evaluating Pegunigalsidase Alfa Meets Key Objectives JERUSALEM (dpa-AFX) - Protalix BioTherapeutics, Inc. (PLX), and Chiesi Global Rare Diseases, a unit of Chiesi Farmaceutici, reported final study results from the BRIDGE phase III switch-over clinical trial evaluating Pegunigalsidase Alfa for the treatment of Fabry Disease. Final results showed substantial improvement in renal function as measured by mean annualized estimated Glomerular Filtration Rate (eGFR slope) in both male and female patients who were switched from agalsidase alfa to pegunigalsi...